Journal of Neuroimmunology · Jul 17, 2016

SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review

By Nimmagadda VK, Makar TK, Chandrasekaran K et al.

Neurodegeneration is an important determinant of disability in multiple sclerosis (MS) but while currently approved treatments reduce inflammation, they have not been shown to reduce neurodegeneration. SIRT1, a NAD dependent protein deacetylase, has been implicated in the pathogenesis of neurodegeneration in neurological diseases including MS. We have studied the role of SIRT1 in experimental autoimmune encephalomyelitis (EAE) and found evidence for a neuroprotective role. In this review we summarize the most recent findings from the use of SIRT1 activators and SIRT1 overexpression in transgenic mice. These data support provide a rational for the use of SIRT1 activators in MS.

doi.org/10.1016/j.jneuroim.2016.07.007PubMed 27474445Interventions